

Singular Health Group Ltd: SHG

ASX Announcement

20 December 2021

Singular Health Partners with Customa to Build Custom Stoma Seals

- On the back of Singular Health's successful IMCRC Active grant application to add surface scanning capability to its 3Dicom software and create 3Dicom Surface, the Company has signed a binding Memorandum of Understanding (MoU) with Customa Pty Ltd.
- Customa Pty Ltd will pay \$50,000 to adapt the 3Dicom Surface software to scan the area around stomas and design patient specific stoma seals that fit snugly.
- Customa Pty Ltd to will license 3Dicom Surface for \$10,000 per annum plus \$5.00 per scan upon the manufacture of 100 customised stoma seals using this process.

20 December 2021 – Singular Health Group Ltd (ASX: SHG) ("Singular Health", or "the Company") is pleased to announce that it has been successful in engaging its first commercial partner for 3Dicom Surface, Customa Pty Ltd. The 3Dicom Surface software will be tailored to provide a process to scan and generate a 3D printable mould where patient specific silicone seals are cast and used by patients to reduce leakage of colostomies.

Singular Health is focused on commercialising the 3Dicom software as the core platform for the Scan to Surgery™ workflow and jointly developing research and commercial opportunities which fit the Company's vision of delivering better health outcomes. The Company has executed a binding MoU with Customa Pty Ltd, a Perth-based medical device company, to apply the outcomes of the IMCRC Activate project towards accelerating the design of custom stoma seals and providing a higher quality of life to the more than 45,000 Australians living with a stoma.

According to the "Global Stoma Care Market Report 2021", the global stoma care market size is expected to expand at a CAGR of 6.6% from 2021 to 2028, to reach USD 785.6 million by 2028.

Customa Pty Ltd will provide an upfront development fee of \$50,000 to Singular Health, along with an ongoing annual license fee of \$10,000 and \$5 per stoma scan upon successful completion of the project - defined as the milestone of manufacturing 100 customised stoma seals using this process.

The current project development timetable hopes to see 3Dicom Surface capable of undertaking stomas scans to a standard ready to manufacture stoma seals within 9 months. This timetable is indicative only and subject to change based on the success or otherwise of the R&D program being implemented to develop 3Dicom Surface.

The MOU is not subject to any conditions precedent and work on this Project will commence immediately. The MOU was negotiated confidentially with Customa Pty Ltd in tandem with finalisation of the 3Dicom Surface R&D project terms (which have been fully detailed in the Company's separate ASX announcement also released today).




Figure 1: A Custom Stoma Seal manually designed to be patient-specific and fit to skin around the stoma.

This Project is further confirmation of the Company's strong R&D activities and the ability to apply the core 3Dicom software to numerous clinical applications to improve health outcomes and quality of life.

The Company's focus on collaboratively developing commercial opportunities with existing industry partners for various applications continues to develop extensive channels to market the 3Dicom software, Artificial Intelligence (AI) models, and 3D printing of personalised surgical implants.

Thomas Hanly, Singular Health's Chief Executive Officer, said:

"We are very proud to be rounding out a highly successful year for Singular Health with another collaborative commercial project that showcases our ability to develop patient specific medical devices from radiological, and now surface, scans.

With this collaboration, our CSIRO R&D projects, and steady progress on our regulatory processes, we are excited for the next year ahead."

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Founded in 2017, Singular Health is a medical technology company that has developed and commercialised the proprietary Volumetric Rendering Platform ("VRP") for the 3D and VR visualisation of anatomy using standard radiological imagery.

Singular Health is committed to developing technologies that provides patients and practitioners alike with access to personalised, enhanced medical data to inform better health decisions and is currently developing and deploying software products that are built upon the proprietary VRP on a global scale through a direct-to-consumer Software-as-a-Service ("SaaS") model.

About Scan to Surgery:

Scan to Surgery™ is a disruptive technology driven process that revolutionises the planning and execution of surgical procedures, reducing cost and improving patient outcomes. Built on the backbone of MFTP, incorporating 3D/VR scan review with virtual surgical planning software and utilising local additive manufacturing facilities, Scan to Surgery™ aims to rapidly deliver patient-specific solutions.

About Customa Pty Ltd:

Customa Pty Ltd, a Perth-based company, is currently commercialising the manufacture of innovative patient specific stomas to assist the more than 45,000 Australians living with stomas. Through the manufacture of bespoke stoma seals that reduce leaking and provide better adhesion to skin, Customa is improving patient care and quality of life.